Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | PLG | P00747 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568655 | 0.99 | EPHX2 (0.44) | EPHX2F2MEN1KMT2APLG | |
| SCHEMBL5568337 | 0.82 | EPHX2 (0.50) | EPHX2F2MEN1KMT2APLG | |
| SCHEMBL5568118 | 0.81 | EPHX2 (0.51) | EPHX2F2MEN1KMT2APLG | |
| SCHEMBL5568558 | 0.80 | MEN1 (0.45) | EPHX2F2MEN1KMT2APLG | |
| SCHEMBL5568654 | 0.79 | MEN1 (0.43) | EPHX2F2MEN1KMT2APLG | |
| SCHEMBL5567643 | 0.77 | MEN1 (0.53) | EPHX2F2MEN1KMT2APRSS1 | |
| SCHEMBL5567364 | 0.76 | RXFP1 (0.49) | EPHX2F2MEN1KMT2APRSS1 | |
| SCHEMBL5568503 | 0.75 | MEN1 (0.48) | EPHX2F2MEN1KMT2APRSS1 | |
| SCHEMBL5568033 | 0.74 | MEN1 (0.50) | EPHX2F2MEN1KMT2APRSS1 | |
| SCHEMBL5565593 | 0.74 | EPHX2 (0.42) | EPHX2F2MEN1KMT2APLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247654-B2 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-24 | — | — | US | claimed |
| US-20050009895-A1 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009895-A1 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | TFPI, HABP2, TFPI2 | EPHX2 1093/4885F2 17/4885MEN1 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.